Category Archives: People

iHerb’s 618 Big Benefits: Rewarding Users in Hong Kong and Southeast Asia

IRVINE, Calif., June 03, 2026 (GLOBE NEWSWIRE) — iHerb, a globally renowned health and wellness e-commerce platform, which has been established for 29 years, recently launched its 618 Peak Shopping Festival (June 11-20) and offered a month-long discount program to give back to users in Hong Kong and Southeast Asia. The platform insists on direct […]

Xcube.bio Strengthens Board with Appointment of Three Distinguished Non-Executive Directors

ZUG, Switzerland, June 03, 2026 (GLOBE NEWSWIRE) — Xcubebio AG, a market entry acceleration engine for innovative biopharma and transformative therapeutics, today announced the appointments of Carinne Brouillon, Pascal Noth and Jaak Peeters to its Board of Directors, adding exceptional expertise in biopharmaceuticals, global strategy, innovation, and commercial leadership to support xcube.bio’s mission to help […]

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, […]

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic […]

SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma

First-in-human study of SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal PRAGUE, Czech Republic, BASEL, Switzerland and BOSTON, June 03, 2026 (GLOBE NEWSWIRE) — SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has […]

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

– Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron’s Veloci-Bi® platforms – – CytomX to receive $37 million target selection payment for two additional programs selected – – Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory […]

MSI Showcases Latest Commercial Surface Innovations at NeoCon 2026

ORANGE, Calif., June 02, 2026 (GLOBE NEWSWIRE) — M S International, Inc. (MSI), the leading supplier of flooring, countertops, wall tile, and hardscaping products in North America, invites attendees to visit booth 163-C at NeoCon 2026 to experience new collections, fresh color palettes, and innovative designs. Join us at The Mart in Chicago for the commercial design industry’s most important […]

GetYourGuide unveils summer 2026’s three defining travel trends

From iconic landmarks to sunset tours and activities, GetYourGuide reveals how global travelers are really spending their summer via market data. BERLIN – June 2, 2026 – GetYourGuide, a leading global online marketplace to discover and book experiences worth traveling for, today reveals three defining trends shaping summer travel in 2026 — drawn from booking […]

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants ages […]

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

– The INDIGO study met its primary and all key secondary endpoints with statistically significant results – – Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related toxicities – – A Biologics License Application (BLA) for obexelimab in IgG4-RD was submitted to the FDA in May – WALTHAM, Mass., June 02, 2026 […]